| Título: | Short-term Results of Two Treatment Regimens in Ocular Toxoplasmosis: Trimethoprim/Sulfamethoxazole versus Pyrimethamine and Sulfadiazine |
| Autores: |
Mohammad-Mehdi Sadoughi; Shahid Beheshti University, M.C. Masoud Soheilian; Shahid Beheshti University, M.C. Mohammad-Hossein Dehghan; Shahid Beheshti University, M.C. Hassan Behboudi; Gilan University of Medical Sciences, Rasht Arash Anisian; Shahid Beheshti University, M.C. Shahin Yazdani; Shahid Beheshti University, M.C. |
| Fecha: | 2008-12-22 |
| Publicador: | Ophthalmic Research Center |
| Fuente: |
Ver documento |
| Tipo: | |
| Tema: | No aplica |
| Descripción: | PURPOSE: To compare the efficacy of classic treatment for ocular toxoplasmosis (pyrimethamine, sulfadiazine and predinsolone) with a regimen consisting of trimethoprim/sulfamethoxazole (TMP/SMX) [co-trimoxazole] plus predinsolone. METHODS: In a prospective randomized single-blind clinical trial, 59 patients with active ocular toxoplasmosis were randomly assigned to two treatment groups: 29 were treated with pyrimethamine/sulfadiazine and 30 patients received TMP/SMX. Treatment consisted of six weeks treatment with antibiotics plus steroids. Anti-toxoplasmosis antibodies (IgM and IgG) were measured using ELISA. Outcome measures included changes in retinochoroidal lesion size after six weeks of treatment, visual acuity before and after intervention, adverse drug reactions during follow up and rate of recurrence. RESULTS: Active toxoplasmosis retinochoroiditis resolved in all patients over six weeks of treatment with no significant difference in mean reduction in retinochoroidal lesion size between the two treatment groups (61% reduction in the classic treatment group and 59% in the TMP/SMX group, P=0.75). Similarly no significant difference was found in visual acuity after treatment between the two groups [mean visual acuity after treatment was 0.12 LogMAR (20/25) in classic treatment group and 0.09 LogMAR (20/25) in TMP/SMX group, P = 0.56]. Adverse events were similar in both groups with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 14 months of follow up was 6.7% with no significant difference between the treatment groups (P = 0.48). CONCLUSION: Drug efficacy in terms of reduction in retinal lesion size and improvement in visual acuity was similar between a regimen of TMP/SMX and the classic treatment of ocular toxoplasmosis with pyrimethamine and sulfadiazine. Therapy with TMP/SMX appears to be an acceptable alternative for the treatment of ocular toxoplasmosis. |
| Idioma: | Inglés |
1 Outcomes of Surgical Treatment for Retinal Detachment Resulting from Macular Hole in Highly Myopic Eyes por Amir-Khosro Ghaseminejad; Kerman University of Medical Sciences, Kerman,Masoud Soheilian; Shahid Beheshti University, M.C.,Arash Anisian; Shahid Beheshti University, M.C.,Hamid Ahmadieh; Shahid Beheshti University, M.C.,Mohsen Azarmina; Shahid Beheshti University, M.C. | 6 Changing Concepts in the Surgical Repair of Primary Retinal Detachment: The Odyssey of a Leaking Break (part 1) por Ingrid Kreissig; Department of Ophthalmology, Clinical Faculty, Mannheim University, Heidelberg |
2 Subtenon Carboplatin in the Management of Intraocular Retinoblastoma por Reza Karkhaneh; Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran,Naseh Mohammadi; Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran,Hormoz Chams; Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran,Parvaneh Vosough; Iran University of Medical Sciences, Tehran,Mansour Rezaei; Iran University of Medical Sciences, Tehran,Naser Valaei; Shahid Beheshti University, M.C. | 7 Ocular Complications of Brucellosis: a Case Report por Ali-Reza Lashay; Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran,Mohammad-Reza Manaviat; Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran,Reza Azimi; Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran,Mohammad Riazi; Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran |
3 Prophylactic Effects of Mitomycin-C on Regression and Haze Formation in Photorefractive Keratectomy por Hassan Hashemi; Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran,Mohammad-Reza Taheri; Noor Eye Clinic, Tehran,Akbar Fotouhi; Health Faculty, Tehran University of Medical Sciences, Tehran | 8 Early Results of Autologous Cultivated Limbal Stem Cell Transplantation in Total Limbal Stem Cell Deficiency por Mohammad Ali Javadi; Shahid Beheshti University, M.C.,Bahram Einollahi; Shahid Beheshti University, M.C.,Alireza Baradaran Rafiei; Shahid Beheshti University, M.C.,Hossein Baharvand; Rooyan Research Center, Tehran, Iran,Marzieh Ebrahimi; Rooyan Research Center, Tehran, Iran,Nasrin Rafati; Shahid Beheshti University, M.C.,Mojgan Rezaei Kanavi; Shahid Beheshti University, M.C. |
4 Etiology of Oculomotor Nerve Paralysis por Abdul-Reza Tabassi; Tehran University of Medical Sciences, Tehran,Ali-Reza Dehghani; Isfahan University of Medical Sciences, Isfahan,Hamid Mosayebi; Tehran University of Medical Sciences, Tehran | 9 Amniotic Membrane Transplantation for Congenital Distichiasis por Hossein Saloor; Shahid Beheshti University, M.C.,Maryam Aletaha; Shahid Beheshti University, M.C. |
5 Visual Function following Treatment of Optic Neuritis por Majid Abrishami; Mashhad University of Medical Sciences,Mir-Naghi Moosavi; Mashhad University of Medical Sciences,Abbas Azimi-Khorasani; Mashhad University of Medical Sciences,Azardokht Vazifeshenas; Mashhad University of Medical Sciences | 10 Comparison of Two Methods for Upper Lid Fascia Lata Sling in Congenital Blepharoptosis: a Randomized Clinical Trial por Abbas Bagheri; Shahid Beheshti University, M.C.,Maryam Aletaha; Shahid Beheshti University, M.C.,Hossein Saloor; Shahid Beheshti University, M.C.,Shahin Yazdani; Shahid Beheshti University, M.C. |